معرفی
Mary Thomson serves as an Assistant Professor in the Department of Medicine - Gastroenterology, Hepatology, Nutrition Division at the University of Minnesota Medical School. Her academic career focuses on clinical hepatology and gastroenterology with particular expertise in liver diseases and their complications.
Dr. Thomson's research interests span multiple critical areas in hepatology including liver cirrhosis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), cholestatic pruritus, and the intersection of liver disease with bone health. Her work demonstrates strong focus on clinical outcomes research, therapeutic interventions, and identifying unmet needs in patient care for those with chronic liver conditions.
Analysis of her recent publications reveals consistent contributions to understanding complications of liver disease, particularly osteoporosis in cirrhosis patients and screening for harmful alcohol use. Her research shows growing emphasis on therapeutic interventions for cholestatic liver diseases and their complications, with multiple active clinical trials investigating novel treatments.
Dr. Thomson has secured significant research funding as Principal Investigator on six major projects between 2020-2025, including industry-sponsored clinical trials with Mallinckrodt Pharmaceuticals, CymaBay Therapeutics, and Escept Pharmaceuticals. Her grant portfolio demonstrates expertise in both observational studies and interventional clinical trials.
Her laboratory and research team appears focused on clinical hepatology research with strong collaborations across multiple institutions, particularly with Northwestern University and industry partners. The research group maintains active investigation into novel therapeutic approaches for challenging liver conditions, with particular emphasis on improving quality of life for patients with chronic liver diseases.
